GLP1R and metabolic dysfunction-associated steatohepatitis: For example, a phase 2 clinical trial showed that GLP-1 receptor agonist semaglutide can improve NASH resolution without worsening liver fibrosis compared to placebo, but semaglutide did not significantly ameliorate liver fibrosis in NASH patients [146].